02/03/2026

BIZ & FINANCE MONDAY | MAR 2, 2026

/thesuntelegram FOLLOW / Malaysian Paper

ON TELEGRAM m RAM

16

LAC Med posts higher FY25 earnings

remain committed to maintaining margin discipline and operational efficiency across all segments.” On the regional front, the group officially commenced operations of PT Fairmed Nusajaya Imaging, a 95%-owned subsidiary company in July 2025, with all necessary licenses obtained from the relevant regulatory authorities in Indonesia. Entering the new financial year, its Indonesian subsidiary will be able to capture earnings fully, supported by an established existing base Alpinion products in the region. In the fourth quarter ended Dec 31, 2025, group revenue stood at RM78.7 million with net profit of RM9.8 million. As this is the group’s second interim financial report on consolidated results, there is no comparison to the preceding year corresponding quarter. LAC Med was listed on the Main Market of Bursa Malaysia Securities Bhd on Dec 10, 2025.

Malaysia’s

hospitals

to

build

expenses of RM2.6 million from its public listing exercise in 2025. Adjusting for this, the group’s core net profit would have been RM24.5 million in FY25, a 20.1% increase compared with the previous year. Group CEO Liew Yoon Poh said: “We pride our capabilities in integration. With an expanded product range and services, we saw robust demand for our medical devices and solutions during the year, driven by expansion in the private healthcare sector in Malaysia. “As healthcare demand continues to rise, LAC Med is ready to provide state of the art medical technology solutions, supported by AI powered assistance that accelerates diagnosis and decision making in hospitals and clinics.” Looking ahead, he added, they will continue to drive initiatives across their 11 brands to propel growth from multiple diagnostics areas, while spearheading digitalisation in

propelled by higher contribution from the Supply and Integration of Medical Devices segment, growing 48.6% to RM128.6 million from RM86.5 million previously. Furthermore, revenue from the Supply of Related Products and Services segment increased 61.5% RM24.5 million, from RM15.2 million previously. Segment growth was driven by higher sales of medical consumables and increased contributions from healthcare IT solutions, further boosting the group’s recurring income to sustain earnings. Meanwhile, revenue from the Supply of Medical Equipment segment recorded RM48.5 million in FY25, down 40.5% from a high base of RM81.5 million in the previous year. The decline was attributed to a significant order that the group had secured from a public hospital and completed in the previous year. During the financial year, the group had expensed one-off listing

PETALING JAYA: MedTech solutions provider, LAC Med Bhd recorded a 7.5% increase in net profit to RM21.9 million in the financial year ended Dec 31, 2025 (FY25), from RM20.4 million previously, underpinned by continued demand from private hospitals for medical devices and growing recurring income stream. Fuelling the group’s earnings, revenue in FY25 rose 10.0% to RM201.6 million, from RM183.2 million previously. The revenue increase was o MedTech solutions provider expands recurring revenue base with multi-year contract wins

recurring income streams. At the same time, LAC Med will focus on building operational efficiency and strengthening local partnerships to accelerate market penetration in Indonesia. LAC Med’s order book as at Feb 15 stood at RM216.7 million, including new wins worth RM20.4 million secured after its public listing in December 2025, to deliver medical laboratory consumables and products over a four year period. Comparatively, the order book stood at RM184.6 million as at Oct 15, 2025, the latest practicable date of the IPO prospectus. “The recurring supply arrange ments from the new wins will enhance our revenue visibility and position us for entry into previously unaddressed market segments,” Liew added. While the group continues to expand the recurring and con sumables-based revenue streams, we

KSL’s Q4 net profit grows 66.4% to RM258.4 million

JOHOR BAHRU: Johor property developer, KSL Holdings Berhad saw its net profit grow 66.4% to RM258.4 million in the fourth quarter ended Dec 31, 2025 (4Q25), from RM155.3 million a year ago. The robust earnings growth was supported by a 41.1% increase in revenue to RM548.7 million, from RM388.9 million a year ago, driven by higher revenue recognition from ongoing projects. The group achieved new property sales of RM1.35 billion for the full year ended Dec 31, 2025 (FY2025), surpassing its initial target of RM1.2 billion. Unbilled sales stood at RM850 million as at Dec 31, 2025, laying a strong foundation for earnings visibility. Executive director, Khoo Lee Feng said: “As the Johor-Singapore Special Economic Zone (JS-SEZ) continues to gain traction, we are accelerating our development pipeline to meet the growing homeownership demand. For FY2026, we are focusing on integrated township projects, complemented by selective high-rise developments to capitalise on the property upcycle in Johor.” He added the company remain committed to disciplined execution across its sizeable 5,000-acre landbank, predominantly situated within the JS-SEZ. This strategically positioned landbank supports a sustainable development pipeline over the next 10 to 15 years, providing the group with earnings visibility while capturing future growth opportunities. Building on the positive demand, the group has set a property sales target of RM1.6 billion for the current financial year ending Dec 31, 2026 (FY2026), underpinned by upcoming integrated township developments and sustained demand for well-located homes across Johor. At the same time, the group’s Property Investment segment will be further strengthened by ongoing asset enhancement initiatives, including tenant mix optimisation, rental yield adjustments, and event hall expansions, all aimed at enhancing recurring revenue streams. For FY2025, the group’s revenue grew 10.0% to RM1.51 billion, from RM1.38 billion in the previous year. The Property Development segment was the primary revenue driver, contributing RM1.24 billion in total revenue, representing a 10.6% increase from RM1.12 billion previously. The Property Investment segment also contributed significantly, achieving RM274.7 million in revenue in FY2025.

Astaka ventures into healthtech sector JOHOR BAHRU: Johor-based Astaka Holdings Limited plans to venture into the healthtech sector as it explores new future growth drivers for the group. revenue base, while benefiting from the ability to procure our own LED lighting solutions for our development projects.” (From left) Astaka chief financial officer Ang Siew Peng, Khong, Lim and Evergrown chief operating officer Choy Chee Cheong.

brand of consumer-focused healthtech light products in 3Q 2026. Singapore will be our launch market, but in the future, we plan to expand regionally,” he added. Evergrown Holdings CEO Nelson Lim said: “We are excited to kick off this exclusive partnership with Astaka, one of the most prominent developers of high-end real estate projects in Johor. While we have completed over 700 residential installations in Malaysia since our inception, our main customer base is within the commercial and industrial sectors. “There is a clear opportunity to enter the consumer market in Singapore, where there is a growing residential property market and over a million Housing & Development Board (HDB) units. “Both Astaka and Evergrown Group share a mutual vision to promote safer and more sustainable lived environments for our customers. In light of deepening business and trade links among companies in the Johor-Singapore Special Economic Zone, we believe that entering Singapore through a partnership with an SGX-listed company will be the perfect platform for our future expansion.”

As a developer of premium serviced residences in Johor such as The Astaka, Arden and Aliva, he added, they are constantly looking to enhance living experiences through the integration of innovative technologies that promote sustainability and the well-being of their communities. “When we came across Evergrown Group’s range of pioneering and proven healthtech light products, we quickly became customers ourselves,” he said, adding that with heightened hygiene awareness post-Covid-19, demand for “healthtech light” and sterilisation lighting solutions has continued to expand globally. As Singapore is a healthtech innovation hub and one of the world’s cleanest countries, Khong said they saw the perfect opportunity to introduce Evergrown’s products to the local consumer market. “Leveraging our expertise in residential property development and with the help of external consultants, we are now assessing the market with the goal of launching our own

Astaka recently signed an exclusive agreement with a subsidiary of Johor-based Evergrown Holdings Bhd, a manufacturer of EV SUN “healthtech light” products that use sterilisation lighting technology to enhance health by creating more hygienic and secure environments. Under the terms of the Agreement, Astaka will engage Evergrown Group to manufacture certain products as determined by Astaka and mutually agreed upon by both parties, which Astaka will then purchase and market under its own tradename and trademark. Developed using in-house technology, Evergrown Group’s products are currently used mainly in commercial and industrial applications. Its customers include most well-known hospital chains, world-renowned food and beverage brands and manufacturers as well as major government institutions in Malaysia. Executive director and CEO, Allen Khong said: “By venturing into the consumer healthtech sector, our goal is to expand our